Upregulation of interleukin-19 in severe asthma: a potential saliva biomarker for asthma severity

Fatemeh Saheb Sharif-Askari, Narjes Saheb Sharif-Askari, Swati Goel, Bassam Mahboub, Abdul Wahid Ansari, Mohamad-Hani Temsah, Adel M. Zakri, Elaref Ratemi, Rifat Hamoudi, Qutayba Hamid, Rabih Halwani

Source: ERJ Open Res, 7 (3) 00984-2020; 10.1183/23120541.00984-2020
Journal Issue: July
Disease area: Airway diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Fatemeh Saheb Sharif-Askari, Narjes Saheb Sharif-Askari, Swati Goel, Bassam Mahboub, Abdul Wahid Ansari, Mohamad-Hani Temsah, Adel M. Zakri, Elaref Ratemi, Rifat Hamoudi, Qutayba Hamid, Rabih Halwani. Upregulation of interleukin-19 in severe asthma: a potential saliva biomarker for asthma severity. ERJ Open Res, 7 (3) 00984-2020; 10.1183/23120541.00984-2020

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Distribution of biomarkers in severe asthma and severe uncontrolled asthma
Source: Virtual Congress 2021 – Pearls in asthma and respiratory burden research
Year: 2021



Immunoproteasome function as a potential biomarker for asthma severity and response to therapy
Source: Virtual Congress 2021 – Emerging new mechanisms of chronic lung disease
Year: 2021


Determination of value the biomarkers of an inflammation at atopic asthma exacerbation caused by respiratory infection
Source: Annual Congress 2010 - From rare towards common lung diseases: diagnostic and monitoring challenges
Year: 2010

The role of Hs-CRP in evaluating asthma severity and asthma control
Source: Annual Congress 2010 - Asthma aspect of diagnosis and criteria for follow-up
Year: 2010

Markers of severity and inflammatory profile during exacerbations of severe asthma.
Source: International Congress 2017 – Airway disease and exacerbations
Year: 2017

ECP in saliva: marker of disease activity in mild to moderate pediatric asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 142s
Year: 2002

Leptin as a specific marker of risk factors in severe bronchial asthma
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009


Measuring inflammation inpaediatric severe asthma: biomarkers in clinical practice
Source: Breathe, 16 (1) 889; 10.1183/20734735.0301-2019
Year: 2020



Role of interferon-gamma as a marker of asthma severity and control
Source: International Congress 2019 – Modelling and monitoring of airway diseases
Year: 2019


The role of biomarkers in the management of severe asthma
Source: International Congress 2019 – Severe asthma guidelines: update 2019
Year: 2019


Clinical markers of disease severity in the assessment of airway inflammation in patients with persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 335s
Year: 2001

Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline
Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges
Year: 2009

Endogenous airway acidification in children with chronic asthma: clinical implications
Source: Eur Respir J 2003; 22: Suppl. 45, 397s
Year: 2003

The role of airways 17ß-estradiol as a biomarker of severity in post-menopausal asthma
Source: Virtual Congress 2020 – Respiratory homeostasis and structural changes in disease
Year: 2020


Induced sputum in asthma and COPD: meassuring type and inflammation activity
Source: Eur Respir J 2003; 22: Suppl. 45, 76s
Year: 2003

Expression of the β2-adrenoreceptor and M3-cholinoreceptor genes in patients with different severity of asthma and BHR level
Source: Annual Congress 2012 - Phenotypes and mechanisms of treatment of asthma
Year: 2012


IL-33 mRNA in induced sputum cells from allergic rhinitis and asthma patients: a marker of Th-2 phenotype status?
Source: International Congress 2017 – Monitoring asthma control
Year: 2017

Small airways function: evaluation in a population of adult patients with severe asthma and potential use as a response biomarker for anti-IL5 therapy
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020